Urogenital Neoplasms  >>  sagopilone (BAY86-5302)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sagopilone (BAY86-5302) / Bayer
NCT00246688 / 2005-000635-15: Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Completed
2
63
Europe
Sagopilone (BAY86-5302 , ZK219477)
Bayer
Ovarian Neoplasms
06/07
06/07
NCT00751205 / 2008-000879-26: Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Completed
2
150
Europe
Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid, Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Bayer
Prostate Cancer, Ovarian Cancer
02/10
08/10

Download Options